Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

While the ACIP made six recommendations in April, Kennedy has only endorsed three so far; they outline who can use newly licensed chikungunya vaccines. Three others, related to a new meningococcal ...

Mosquitoes can tranmist dengue virus, which has already caused local cases in Florida in 2025... | Clinical And Molecular Dx ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications.

US health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible side effects.

The U.S. government advised American travelers age 60 and older not get a chikungunya vaccine as it investigates possible side effects. The Centers for Disease Control and Prevention and the Food and ...

Chikungunya isn't prevalent in the U.S., but travelers are being told to be cautious about getting the vaccine for the ...

Early COVID suppression could have prevented 180,000 UK deaths, study reveals … FDA, CDC pause chikungunya vaccine for adults ...

A vaccine designed to protect against chikungunya, a mosquito-borne illness, has been temporarily paused for individuals aged 60 and older.

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...